Bases moleculares de la hipertrofia ventricular izquierda. Papel del estrés oxidativo

Revista Cubana de Investigaciones Biomedicas

Volumn 16, Issue 2, 1997, Pages 083-92

  Valle, Félix Broche ^a,b   Sánchez, Marisol Peña ^a   Céspedes Miranda, Ela M ^a   García Piñeiro, José C ^a   Herrera, José Castillo ^a  

^a NATL CENTER FOR SCIENTIFIC RESEARCH   (Cuba)

^b INSTITUTO SUPERIOR DE CIENCIAS MÉDICAS DE LA HABANA   (Cuba)

Author keywords

Hypertension complications; Hypertrophy; Left ventricular physiopathology; Oxidative stress; Renin angiotensin system

Indexed keywords

EID: 53249105781     PISSN: 08640300     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (55)

1. Stein J. Medicina interna. La Habana: Editorial Científico- Técnica, 1987,vol1,t1:573-90.
2. Rigol RO, Pérez CF, Perea CJ, Fernández SJ, Fernández MJ. Medicina general integral. La Habana: Editorial Pueblo y Educación, 1987,t3:11-23.
3. Chobaninan AV, Brecher PI, Haudenschild CC. Effects of hypertension and antihypertensive therapy on atherosclerosis: state of the art lecture. Hypertension 1986;8(Suppl 1):15-21.
4. Kannell WB. Some lessons in cardiovascular epidemiology from Framingham. Am J Cardiol 1976;37:269-82.
5. Kannell WB, Castelli WP, Mellumara AM, McKee PH, Fernleib M. Role of blood pressure in the development of congestive heart failure. N Engl J Med 1972;297:781-7.
6. Coca A, Sierra A de la. Mecanismos patogenéticos de la hipertrodia cardíaca en la hipertensión arterial. Med Clin (Barc) 1991; 97:667-76.
7. Pelouch V, Dixon I, Golfman L, Beamish R, Dhalla N. Role of extracellular matrix proteins in heart function. Mol Cell Biochem 1994;129:101-120.
8. Page E, McCalister LP. Quantitative electron microscopic description of heart muscle cells. Application to normal, hyperthrophied and thyroxinstimulated heart. Am J Cardiol 1973;31:172-81.
9. Bashey RI, Martínez-Hernández A, Jiminez SA. Isolation, characterization and localization of cardiac collagen type VI. Associations with other extracellular matrix components. Circ Res 1992;70:1006-1007.
10. Eghbali M, Tomek R, Suthatme VP, Wood Ch, Bhambi B. Different effects of transforming growth factors and phorbol myristate acetate and cardiac fibroblasts. Regulation of fibrillar collagen mRNAs and expression of early transcription factors. Circ Res 1991;69:483-90.
11. Sporm MB, Roberts AB. The transforming growth factors Bs. En: Sporm MB, Roberts AB. Peptide growth factors and their receptors. 1990:
12. Gibbons G, Pratt RE, Dzau VJ. Vascular smooth muscle cells hypertrophy vs hyperplasia. Autocrine transforming growth factor B1 expression determines growth response to angiotensin II. J Clin Invest 1992;90:456-61.
13. Stouffer GA, Owens GK. Angiotensin II induced mitogenesis of spontaneously hypertensive rat derived cultured smooth muscle cells is dependent on autocrine production of transforming growth factor B. Circ Res 1992;70:820-8.
14. Graier FW, Sturek M, Kukowets W. Ca2+ regulation and endothelial vascular function. Endothelium 1994;1:223-36.
15. Lewis M, Shah A. Endothelial modulation of myocardial contraction. Endothelium 1994;1:237-43.
16. Battistini B, O'Donnell LJ, Warner TD, Fournier A, Farthing MJ, Vane JR. Characterization of endothelin receptors in the isolated gall blader of the guinea pig evidence for an additional ET receptor subtype. Br J Pharmacol 1994;112(4):1244-50.
17. Corder R, Vane JR. Radioimmunoassay evidence that the pressor effect of big endothelin-1 is due to local conversion to endothelin-1. Biochem Pharmacol 1995;49(3):375-80.
18. Black D, Jones NF. Enfermedades renales. La Habana: EditorialE Científico-Técnica, 1985;t1:62.
19. Hipertensión esencial. Clin Méd Norteam 1987.
20. Lloyd HS, Samuel OT. Fisiopatología: principios biológicos de la enfermedad. La Habana: Editorial Científico-Técnica, 1986;t2:893.
21. Morgan R, Stewart JM, Vavrek RJ, Hassid A. Effects of bradykinin and angiotensin II on intracellular calcium dynamics in endothelial cells. Am J Physiol 1987;253:C588-98.
22. Brechler V, Levens N, De Gasparo M, Bottari S. Angiotensin AT2 receptor mediated inhibition of particulate guanylate cyclase: a link with protein tyrosine phosphatase stimulation? Recept Chann 1994;2(2):79-87.
23. Brechler V, Reichlin S, De Gasparo M, Bottari S. Angiotensin II stimulates protein tyrosine phosphatase activity through a G protein independent mechanism. Recept Chann 1994;2(2):89-97.
24. Zeiher AM, Schchinger V. Coronary endothelial vasodilator dysfunction: clinical relevance and therapeutic implications. Z Kardiol 1994;83(Suppl 4):7-14.
25. Geer P van der, Hunter T, Lindberg R. Receptor protein-tyrosine kinases and their signal transduction pathways. Annu Rev Cell Biol 1994;10:251-337.
26. Secchi J. Effects of subchronic treatment with trandolapril and enalapril on cardiovascular morphologic alterations in the aged spontaneously hypertensive rat with heart failure. J Cardiovasc Pharmacol 1994;23(Suppl 4s):30-7.
27. Kuchansk J. Significance of mitochondrial Ca2+ transport in ischemic injury and myocardial protection. Bratisl Lex Listy 1994;95(9):391-4.
28. Vademecum internacional. 36 ed. Madrid: Medicom, 1995.
29. Haznedaroglu IC. Effects of ACE inhibition on left ventricular dimensions and haemodynamics in systemic hypertension, a radionuclide and echocardiographic study. Cent Afr J Med 1995;41(4):118-23.
30. Dahlof B, Pennert R, Hansson L. Reversal of left ventricular hypertrophy in hypertensive patients. A metaanalysis of 109 treatment studies. Am J Hypertens 1992;5:95-110.
31. Enstrm J, Thulin T, Lindholm LH. Comparison between enalapril and lisinopril in mild-moderate hypertension. A comprehensive model for evaluation of drug efficacy. Blood Press 1992;1(2):102-7.
32. Rengo F. Comparison of the safety and efficacy of dilapril with enalapril in patients with congestive heart failure. Am J Cardiol 1995;75(16):25F-28F.
33. Vuorinen MH, Yki JH. Effects of enalapril on insulin resistance. Metabolism 1995;44(1):85-9.
34. Cavanagh EM de. Oxidative stress and renal dysfunction in rats treated with enalapril. FEBS Lett 1995;36(1):22-4.
35. Why HJ, Ansell H, Patel VB, Wassif WS, Reeves J, Sidding T, et al. Antioxidant status in hypertension and effects of angiotensin converting enzyme inhibition. Biochem Soc Trans 1995;23(2):224S.
36. Romero D, Villalba Martin M, Bueno J. Papel de la prooxidación y la antioxidación en la etiología de la hipertensión arterial. Med Clin (Barc) 1991;97:542-51.
37. Sohal RS. Superoxide anion radical production in different animal species. Mech Ageing Dev 1989;49:129-35.
38. Chang LY, Molecular immunocytochemistry of the CuZn superoxide dismutase in rat hepatocytes. J Cell Biol 1988;107:2169.
39. Pryor WA. A festschfift volume celebrating the 20th anniversary of superoxide dismutase. Free Rad Biol Med 1988;5:271.
40. Broche VF, Romero SA, Olembe SE, Fernández E, Céspedes ME, García J, et al. Aprotinin effects related to oxidative stress in cardiosurgery with mechanical cardiorespiratory support. Ann NY Acad Sci 1996;793:521-4.
41. Sagar S. Oxigen free radicals in essential hypertension. Roll Gell Brochen 1992;111(1-2):103-8.
42. Kooij A. A reevaluation of the tissue distribution and physiology of xanthine oxidoreductase. Histochem J 1994;26(12):889-95.
43. Halliwell B. Free radicals and antioxidants: a personal view. Nutr Rev 1994;1:253-65.
44. Kucharsk J, Gvozdjkov A, Herichov I, Gvozdjk J. Significance of nitochondrial Ca2+ transport in ischemic injury and myocardial protection. Bratisl Lek Listy 1994;95(9):391-4.
45. Flaherty JT. Reperfusion injury. Free Rad Biol Med 1988;5:409-19.
46. Schoenberg MH, Beger HG. Oxygen radicals and postischemic organ damage: pathophysiology, clinical relevance and therapy. Zentralbl Chir 1995;120(3):174-85.
47. Ferrari R. Oxygen free radicals at myocardial level: effects of ischemia and reperfusion. Adv Exp Med Biol 1994;366:99-111.
48. Hearse D. Xanthine oxidase: a critical mediator of myocardial injury during ischemia and reperfusion? Acta Physiol Scand 1986;(Suppl 548):65-78.
49. Buja M, Bick RJ. Control and modulation of neonatal myocyte calcium movements by cytokines. Promega Notes 1994;47:6-9.
50. Lapenna D, Mezzetti A, Giola S de, Consoli A, Festi D, Di Llio C, et al. Transmural distribution of antioxidant defences and peroxidation in the rabbit left ventricular myocardium. Pflugers Arch 1994; 427(5-6):432-6.
51. Ji LL, Fu RG, Mitchell EW, Griffiths M, Waldrop TG, Swartz HM. Cardiac hypertrophy alters myocardial response to ischemia and reperfusion in vivo. Acta Physiol Scand 1994;151(3):279-90.
52. Engelman DT, Watanabe M, Engelman RM, Rousou JA, Kisin E, Kagan VE, et al. Hypoxic preconditioning preserves antioxidant reserve in the working rat heart. Cardiovasc Res 1995;29(1):133-40.
53. Aucoin MM, Barhoumi R, Kochever DT, Granger HJ, Burghardt RC. Oxidative injury of coronary venular endothelial cells depletes intracellular glutathione and induces HSP 70 mRNA. Am J Physiol 1995;268(4 PART 2):H1651-H1658.
54. Luc G, Fruchart J. Oxidation of lipoproteins and atherosclerosis. Am J Clin Nutr 1991;53:206s-209s.
55. Feuerstein GZ, Ruffolo RR. Carvedilol, novel multiple action antihypertensive agent with antioxidant activity and the potential for myocardial and vascular protection. Eur Heart J 1995;16(Suppl 7):38-42.